References:
Bailey-Kellogg, C., Gutiérrez, A. H., Moise, L., Terry, F., Martin, W. D., & De Groot, A. S. CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnology and Bioengineering, 111 (11), 2170-2182.
Bee, J. S., Tie, L., Johnson, D., Dimitrova, M. N., Jusino, K. C., & Afdahl, C. D. Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product.Biotechnology Progress, 31 (5), 1360-1369.
Cheung, P., Emanuel, A., Heward, J., Maddalena, J., Toth, D., Saward, L., & Kodihalli, S. (2016). Reduced immunogenic response to residual CHO cell protein in recombinant factor IX (IB1001) drug product in normal healthy rabbits. Haemophilia, 22 (3), E220-E222.
Chiu, J., Valente, K. N., Levy, N. E., Min, L., Lenhoff, A. M., & Lee, K. H. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations. Biotechnology and Bioengineering, 114 (5), 1006-1015.
Clarke, C., Gallagher, C., Kelly, R. M., Henry, M., Meleady, P., Frye, C. C., . . . Clynes, M. (2019). Transcriptomic analysis of IgG4 Fc-fusion protein degradation in a panel of clonally-derived CHO cell lines using RNASeq. 116 (6), 1556-1562. doi:10.1002/bit.26958
Congdon, R. W., Muth, G. W., & Splittgerber, A. G. (1993). The Binding Interaction of Coomassie Blue with Proteins. Anal Biochem, 213 (2), 407-413.
de Maria, P. D., & Hollmann, F. (2015). On the (Un)greenness of Biocatalysis: Some Challenging Figures and Some Promising Options.Frontiers in Microbiology, 6 .
de Zafra, C. L., Quarmby, V., Francissen, K., Vanderlaan, M., & Zhu-Shimoni, J. Host cell proteins in biotechnology-derived products: A risk assessment framework. Biotechnology and Bioengineering, 112 (11), 2284-2291.
Dixit, N., Salamat-Miller, N., Salinas, P. A., Taylor, K. D., & Basu, S. K. Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles. J Pharm Sci, 105 (5), 1657-1666.
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit
(1997). CPMP/BWP/382/97 .
FDA. (1997). Points to Consider in the Manufacture & Testing of Monoclonal Products for Human Use. In.
Fischer, S. K., Cheu, M., Peng, K., Lowe, J., Araujo, J., Murray, E., . . . Song, A. Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material. Aaps J, 19 (1), 254-263.
Galanie, S., Thodey, K., Trenchard, I. J., Interrante, M. F., & Smolke, C. D. (2015). SYNTHETIC BIOLOGY Complete biosynthesis of opioids in yeast. Science, 349 (6252), 1095-1100.
Goey, C. H., Bell, D., & Kontoravdi, C. (2018). Mild hypothermic culture conditions affect residual host cell protein composition post-Protein A chromatography. MAbs, 10 (3), 476-487.
Guideline, I. (1999). Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B.International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use .
Gunawan, F., Nishihara, J., Liu, P., Sandoval, W., Vanderlaan, M., Zhang, H. D., & Krawitz, D. (2018). Comparison of platform host cell protein ELISA to process-specific host cell protein ELISA.Biotechnology and Bioengineering, 115 (2), 382-389.
Hall, T., Sandefur, S. L., Frye, C. C., Tuley, T. L., & Huang, L. Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer X1 in Monoclonal Antibody Formulations. J Pharm Sci, 105 (5), 1633-1642.
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y. A., Fischer, S. K., . . . Yen, K. (2015). Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.Thorax, 70 (8), 748-756.
Hogwood, C. E., Bracewell, D. G., & Smales, C. M. Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses.Curr Opin Biotechnol, 30 , 153-160.
Huffman, M. A., Fryszkowska, A., Alvizo, O., Borra-Garske, M., Campos, K. R., Canada, K. A., . . . Yang, H. (2019). Design of an in vitro biocatalytic cascade for the manufacture of islatravir. Science, 366 (6470), 1255-1259. doi:10.1126/science.aay8484
Jawa, V., Joubert, M. K., Zhang, Q., Deshpande, M., Hapuarachchi, S., Hall, M. P., & Flynn, G. C. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics. Aaps J, 18 (6), 1439-1452.
Jiskoot, W., Rispens, T., & Kijanka, G. (2019). Immunogenicity of Therapeutic Proteins. In (pp. 139-150).
John A. McIntosh1*, Z. L., Brian M. Andresen2*, Nastaran Salehi Marzijarani1, Jeffrey C. Moore1, Nicholas M. Marshall1, Margie Borra-Garske3, Jennifer V. Obligacion1, Patrick S. Fier1, Feng Peng1, Jacob H. Forstater1, Matthew S. Winston1, Chihui An1, Wonsuk Chang2, Jongwon Lim2, Mark A. Huffman1, Steven P. Miller1, Fuh-Rong Tsay1, Michael D. Altman2, Charles A. Lesburg2, Dietrich Steinhuebel1, B. Wesley Trotter2, Jared N. Cumming2, Alan Northrup2, Xiaodong Bu1, Benjamin F. Mann1, Mirlinda Biba1, Kaori Hiraga1, Grant S. Murphy1, Joshua N. Kolev1, Amanda Makarewicz1, Weilan Pan1, Iman Farasat1, Rachel S. Bade1, Kevin Stone1, Duan Da3, Oscar Alviso3, Donovan Adpressa2, Erik Guetschow1, Erik Hoyt1, Erik L. Regalado1, Steve Castro1, Nelo Rivera1, Joseph P. Smith1, Fengqiang Wang1, Alejandro Crespo1, Deeptak Verma1, Stephanus Axnanda1, Zachary Dance1, Paul N. Devine1, David Tschaen1, Keith A. Canada1, Paul G. Bulger1, Benjamin D. Sherry1, Matthew D. Truppo1 , Rebecca T. Ruck1, Louis-Charles Campeau1, David Jonathan Bennett2, Guy R. Humphrey1, Kevin R. Campos1, Matthew L. Maddess1. (2022). A kinase-cGAS cascade to synthesize a therapeutic STING activator Nature
Jones, M., Palackal, N., Wang, F., Gaza-Bulseco, G., Hurkmans, K., Zhao, Y., . . . Connolly, T. (2021). “High-risk” host cell proteins (HCPs): A multi-company collaborative view. Biotechnology and Bioengineering, 118 (8), 2870-2885. doi:https://doi.org/10.1002/bit.27808
Lama, L., Adura, C., Xie, W., Tomita, D., Kamei, T., Kuryavyi, V., . . . Tuschl, T. (2019). Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression.Nature Communications, 10 (1), 2261. doi:10.1038/s41467-019-08620-4
Luo, H. B., Tie, L., Cao, M. Y., Hunter, A. K., Pabst, T. M., Du, J. L., . . . Wang, W. K. (2019). Cathepsin L Causes Proteolytic Cleavage of Chinese-Hamster-Ovary Cell Expressed Proteins During Processing and Storage: Identification, Characterization, and Mitigation.Biotechnology Progress, 35 (1).
Novotna, B., Vanekova, L., Zavrel, M., Budesinsky, M., Dejmek, M., Smola, M., . . . Birkus, G. (2019). Enzymatic Preparation of 2’-5’,3’-5’-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations. J Med Chem, 62 (23), 10676-10690. doi:10.1021/acs.jmedchem.9b01062
Patel, R. N. (2006). Biocatalysis: Synthesis of chiral intermediates for drugs. Current Opinion in Drug Discovery & Development, 9 (6), 741-764.
Paulo, J. A. (2016). Sample preparation for proteomic analysis using a GeLC-MS/MS strategy. Journal of biological methods, 3 (3), e45. doi:10.14440/jbm.2016.106
Reetz, M. T. (2013). Biocatalysis in Organic Chemistry and Biotechnology: Past, Present, and Future. Journal of the American Chemical Society, 135 (34), 12480-12496.
Reijers, J. A. A., Malone, K. E., Bajramovic, J. J., Verbeek, R., Burggraaf, J., & Moerland, M. (2019). Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals. British Journal of Clinical Pharmacology, 85 (7), 1418-1426.
Romer, T., Peter, F., Saenger, P., Starzyk, J., Koehler, B., Korman, E., . . . Berghout, A. J. J. o. E. I. (2007). Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. 30 (7), 578-589. doi:10.1007/bf03346352
Saenger, P. (2009). Current status of biosimilar growth hormone.International journal of pediatric endocrinology, 2009 , 370329-370329. doi:10.1155/2009/370329
Smith, J. P., Ralbovsky, N. M., Lauro, M. L., Hoyt, E., Guetschow, E. D., Wang, F., . . . Bu, X. (2022). Quantitation and speciation of residual protein within active pharmaceutical ingredients using image analysis with SDS-PAGE. J Pharm Biomed Anal, 207 , 114393. doi:10.1016/j.jpba.2021.114393
Tal, M., Silberstein, A., & Nusser, E. (1985). Why Does Coomassie Brilliant Blue-R Interact Differently with Different Proteins - a Partial Answer. Journal of Biological Chemistry, 260 (18), 9976-9980.
Vanderlaan, M., Zhu-Shimoni, J., Lin, S. S., Gunawan, F., Waerner, T., & Van Cott, K. E. (2018). Experience with Host Cell Protein Impurities in Biopharmaceuticals. Biotechnology Progress, 34 (4), 828-837.
Wang, F. Q., Richardson, D., & Shameem, M. (2015). Host-Cell Protein Measurement and Control. Biopharm International, 28 (6), 32-+.
Wang, X., Hunter, A. K., & Mozier, N. M. (2009). Host cell proteins in biologics development: Identification, quantitation and risk assessment.Biotechnology and Bioengineering, 103 (3), 446-458.
Weiss W., W. F., Görg A. (2009). Protein Detection and Quantitation Technologies for Gel-Based Proteome Analysis. In S. A. Reinders J. (Ed.), Proteomics. Methods in Molecular Biology™ (Methods and Protocols) . https://doi.org/10.1007/978-1-60761-157-8_4: Humana Press
Wells, A. S., Finch, G. L., Michels, P. C., & Wong, J. W. (2012). Use of Enzymes in the Manufacture of Active Pharmaceutical Ingredients-A Science and Safety-Based Approach To Ensure Patient Safety and Drug Quality. Organic Process Research & Development, 16 (12), 1986-1993.
Wells, A. S., Wong, J. W., Michels, P. C., Entwistle, D. A., Fandrick, K., Finch, G. L., . . . Watson, T. J. (2016). Case Studies Illustrating a Science and Risk-Based Approach to Ensuring Drug Quality When Using Enzymes in the Manufacture of Active Pharmaceuticals Ingredients for Oral Dosage Form. Organic Process Research & Development, 20 (3), 594-601.
Woodley, J. M. (2008). New opportunities for biocatalysis: making pharmaceutical processes greener. Trends in Biotechnology, 26 (6), 321-327.
Zhou, W., Whiteley, A. T., Mann, C. C. D., Morehouse, B. R., Nowak, R. P., Fischer, E. S., . . . Kranzusch, P. J. (2018). Structure of the Human cGAS-DNA Complex Reveals Enhanced Control of Immune Surveillance.Cell, 174 (2), 300-+.
Zhu-Shimoni, J., Yu, C., Nishihara, J., Wong, R. M., Gunawan, F., Lin, M., . . . Vanderlaan, M. (2014). Host Cell Protein Testing by ELISAs and the Use of Orthogonal Methods. Biotechnology and Bioengineering, 111 (12), 2367-2379.